Global Life Science Business Partnering (GLSBP) - May 2024

Highlights of May 2024

1.      Cipla to invest Rs 26 crore (US$~3.1 million) more in Achira Labs.

2.      Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment.

3.      Dr Reddy's and Alvotech ink licensing pact for commercializing denosumab biosimilar.

4.      Zydus Lifesciences inks licensing, supply pact with MSN for generic cancer drug in US market.

5.      Glenmark partners with BeiGene for launching innovative oncology medicines in India.

6.      Biocon Ltd announced that it has signed an exclusive licensing and supply agreement with South Korea's Handok for commercialisation of its complex drug product, synthetic Liraglutide, used in the treatment of chronic weight management.

7.      Bayer and Zydus Lifesciences announced the successful conclusion of their joint venture (JV) - Bayer Zydus Pharma Private Limited (BZPPL).

8.      Merck nears US$1.3 Billion cash deal for eye-drug company EyeBio, WSJ reports.

9.      Asahi Kasei to buy Swedish drugmaker Calliditas for US$1.1 Billion.

10.  Pfizer and AstraZeneca announce new investments of nearly US$1 billion in France.

11.  Novo Nordisk ties up with Metaphore to develop new obesity drugs.

12.  Biocon inks supply, distribution pact with Medix for chronic weight management with Medix for chronic weight management drug in Mexico.

Aagami Updates:

 1.      Aagami is excited to attend the BIO International Convention 2024 in San Diego (June 3-6). 40+ meetings already scheduled. 

2. New Client Win: NanoViricides Engages Aagami to Bolster Partnership Efforts. 

3. Aagami receive contract extension from a US client. 

4. Aagami new offering: AI/ML Powered Business Intelligence via Analytics.

a.      For faster and better decisions with more confidence

b.      Leading to huge savings in time, effort, and cost, while

c.       Propels business growth.

d.      Delivered via Specialist partner.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:  

  1.  Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. 
  2. Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA® & XGEVA®. Other high potential Biosimilars are also available for multiple regions. 
  3. Partnering/Licensing: IP for a small molecule NSAID combination for Migraine and other indications using 505(b)(2). 
  4. Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). 
  5. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies.

For Acquisition:

1.      Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns. 

2.      IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).  

3.      Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

  1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b completed on Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
  2. Seeking US$3 million: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies.
  3. Seeking US$5 million: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance therapeutic assets.

Hope you found the content useful. We welcome your feedback and queries. 

×
Twitter